JP2015525237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525237A5
JP2015525237A5 JP2015518318A JP2015518318A JP2015525237A5 JP 2015525237 A5 JP2015525237 A5 JP 2015525237A5 JP 2015518318 A JP2015518318 A JP 2015518318A JP 2015518318 A JP2015518318 A JP 2015518318A JP 2015525237 A5 JP2015525237 A5 JP 2015525237A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
composition
seq
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525237A (ja
JP6087429B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2013/000983 external-priority patent/WO2013191352A1/en
Publication of JP2015525237A publication Critical patent/JP2015525237A/ja
Publication of JP2015525237A5 publication Critical patent/JP2015525237A5/ja
Application granted granted Critical
Publication of JP6087429B2 publication Critical patent/JP6087429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518318A 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途 Active JP6087429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0066527 2012-06-21
KR20120066527 2012-06-21
PCT/KR2013/000983 WO2013191352A1 (en) 2012-06-21 2013-02-07 New uses of modified human tumor necrosis factor receptor-1 polypeptide

Publications (3)

Publication Number Publication Date
JP2015525237A JP2015525237A (ja) 2015-09-03
JP2015525237A5 true JP2015525237A5 (https=) 2016-04-28
JP6087429B2 JP6087429B2 (ja) 2017-03-01

Family

ID=49768924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518318A Active JP6087429B2 (ja) 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途

Country Status (6)

Country Link
US (1) US9580490B2 (https=)
JP (1) JP6087429B2 (https=)
KR (1) KR101514238B1 (https=)
CN (1) CN104394881B (https=)
BR (1) BR112014031923B1 (https=)
WO (1) WO2013191352A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3288379T (lt) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
CN109311976A (zh) * 2016-06-20 2019-02-05 诺华股份有限公司 使用TNFα拮抗剂治疗干眼症的方法
US20240059768A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer
JP7806062B2 (ja) * 2021-01-14 2026-01-26 ハノル バイオファーマ カンパニーリミテッド タンパーナセプト眼科用組成物を用いた眼球乾燥症の治療
TWI905137B (zh) * 2021-01-14 2025-11-21 南韓商韓兀生物製藥股份有限公司 以含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）之眼用組成物治療乾眼症

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6204270B1 (en) 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
US20040219142A1 (en) 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US20090098136A1 (en) 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CN101591388A (zh) * 2008-05-30 2009-12-02 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
EP2492281B1 (en) 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
KR101273893B1 (ko) 2010-09-13 2013-06-14 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
KR101185310B1 (ko) 2010-12-23 2012-09-21 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법

Similar Documents

Publication Publication Date Title
JP2015525237A5 (https=)
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
JP2012115277A5 (https=)
EA201890220A1 (ru) Вакцина против rsv
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
NL2011626C2 (en) Novel polypeptide and uses thereof.
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
JP2015522264A5 (https=)
WO2014202622A3 (en) Rasamsonia gene and use thereof
JP2017532343A5 (https=)
EA201170917A1 (ru) Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
JP2015524403A5 (https=)
JP2017529326A5 (https=)
Ma et al. Identification, expression and activity analyses of five novel duck beta-defensins
WO2009089822A3 (de) Verwendung eines acetylsalicylsäuresalzes zur behandlung viraler infektionen
JP2016513471A5 (https=)
EP2465935A3 (en) Recombinant human interferon-like proteins
PE20210918A1 (es) Composiciones y metodos para el tratamiento de la distrofia macular
AR060960A1 (es) Peptido, polinucleotico, secuencia celula transgenica, huesped viral, celula huesped, vector de expresion, uso y metodo de antagonistas de alta afinidad de quimioquinas elr- cxc
JP2018529626A5 (https=)
JP2013529916A5 (https=)